Stockreport

Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's [Seeking Alpha]

Annovis Bio, Inc.  (ANVS) 
PDF Annovis' phase 3 program plans will encompass two trials of patients with early Alzheimer's: a six-month study to examine the drug's symptomatic effects and an 18-month [Read more]